RxDoctor Payments Data

Rita Goradia, MD

Family Medicine · Rahway, NJNPI 1174626774

Payments from drug & device makers

$971in general payments, 2019–2025

Across 13 payments — averaging $74.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$372
  • Abbott$263
  • Insmed, Inc.$127
  • Lilly USA, LLC$94
  • Novo Nordisk$69
  • E.r. Squibb & Sons, L.L.C.$30
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,541
Medicare patients
62
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate102$65,758
OzempicSemaglutide63$62,182
EliquisApixaban119$51,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$47,455
TrulicityDulaglutide38$38,384
Breo ElliptaFluticasone/Vilanterol77$33,303
JanumetSitagliptin Phos/Metformin Hcl47$26,918
Fluticasone-SalmeterolFluticasone Propion/Salmeterol134$17,082
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,018
Lantus SolostarInsulin Glargine,hum.Rec.Anlog86$10,305
Albuterol Sulfate HfaAlbuterol Sulfate451$10,077
JardianceEmpagliflozin11$7,863
VascepaIcosapent Ethyl13$7,255
XareltoRivaroxaban12$6,746
Rivastigmine29$4,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$372$80,758146 claims
Novo NordiskOzempic$69$62,18263 claims
Lilly USA, LLCTrulicity$94$38,38438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Rahway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →